Leuprolide inj - UMMC
Leuprolide inj - UMMC
Leuprolide inj - UMMC
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Leuprolide</strong> <strong>inj</strong><br />
Trade name<br />
Drug class<br />
Presentation<br />
Prescriber<br />
Cost<br />
Indication<br />
Location<br />
Administration<br />
Stability / expiry<br />
Compatibility<br />
Incompatibility<br />
Special precautions<br />
Lucrin Depot 3.75mg/ Lucrin Depot 11.25mg<br />
Analog of naturally occurring Gonadotropin releasing hormone (GnRH or LH-RH)<br />
Kit contains 1vial of sterile lyophilized microsphere of leuprolide acetate<br />
incorporated in a biodegradable copolymer of lactic and glycolic acids, one ampoule<br />
of diluent; one syringe with 22 gauge needle and two alcohol wipes<br />
Consultant gynaecologist, urologist, oncologist and paediatric endocrinologist<br />
RM 310- Lucrin Depot 3.75mg<br />
RM 870- Lucrin Depot 11.25mg<br />
Endometriosis: 3.75mg monthly for a maximum of 6 months<br />
Uterine Fibroids: 3.75mg monthly for the treatment of anaemia caused by uterine<br />
leiomyomata in women who fail iron therapy.<br />
Prostate Cancer: 11.25mg 3 monthly for suppression of testosterone production<br />
Precocious Puberty: Dose is titrated upwards until down regulation is achieved<br />
Cawangan Pharm <strong>UMMC</strong>/ Kedai Pharm <strong>UMMC</strong><br />
Administered as a monthly IM or SC <strong>inj</strong>ection:<br />
• Using a syringe and 22 gauge needle, withdraw 1mL of diluent & <strong>inj</strong>ect into<br />
the vial.<br />
• Shake well to obtain a uniform suspension. Suspension will appear milky<br />
Room temperature. Shelf life :36 months<br />
Compatible fluids: NA<br />
Compatible drugs: NA<br />
Compatible via Y site: NA<br />
Compatible in syringe: NA<br />
Incompatible fluids: NA<br />
Incompatible drugs: NA<br />
Contraindication<br />
• Hypersensitivity to leuprolide acetate, similar nonapeptides or any of the<br />
excipents<br />
• Women who are or may become pregnant while receiving the drug<br />
Precautions<br />
• Bone mineral density changes can occur during any hypoestrogenic state, bone<br />
mineral density loss may be reversible after withdrawal of leuprolide acetate<br />
• Patient with metastatic vertebral lesions and or with urinary tract obstruction<br />
should be closely observed during the first few weeks of therapy.
• congestive heart failure or other conditions requiring sodium restriction<br />
• depression<br />
• history of thromboembolism or cardiovascular disease<br />
• increased risk of spinal cord compression<br />
• metastatic vertebral lesions<br />
• occurrence of memory disorders<br />
• transient worsening of prostate cancer symptoms (increased testosterone serum<br />
level)<br />
• undiagnosed abnormal vaginal bleeding<br />
Special notes • Lucrin 3.75mg is used monthly and 11.25mg is used three monthly<br />
• Goserelin or leuprolide has been approved for FOC supply to Government<br />
servants / dependants for treatment of CA prostate. (D&T Bil 5/2006 dated 13 Nov<br />
2006)<br />
• <strong>Leuprolide</strong> approved for 20 children / year to receive FOC supply for treatment<br />
of precocious puberty. Prescription must be written by Paediatric Endocrinologist.<br />
(D&T bil 1/2007 dated 12.1.2007)<br />
Patient Information Possible Side Effects: Increased bone pain, weakness, burning, or tingling of legs or<br />
feet, eecrease in how much or how often you urinate<br />
Prepared/checked by Tan Ching Hooi / PDS / HKD / PL<br />
Date compiled/edition 9 June 2008, 1 st edition